Dr. Romagnoli and co-workers comment: We are indebted to Drs Yamamoto and Adachi for their preciseness about the different mechanism of action of bucolome compared with phenobarbital in animals Adachi and Yamamoto, 1976) . However, our results suggest that the mechanism of serum bilirubin reduction induced by bucolome in man is different from the one reported by Yamamoto and by Semba in Gunn rats (Yamamoto and Adachi, 1974; Semba et al., 1975) . In fact bucolome administration to Gunn rats reduces serum bilirubin rapidly, while our results show that bucolome does not reduce serum bilirubin significantly in newborn infants during the hours after oral administration; its effect is delayed for about 48 hours. Moreover, serum bilirubin continues to fall after discontinuation of treatment. Our results agree with those of Baba (1972/73) in term newborns, and are not consistent with the hypothesis that the mechanism of action of bucolome in man is the displacement of bilirubin from the plasma compartment to the cellular one, as shown in Gunn rats.
We have studied the effect of bucolome on albuminbilirubin binding capacity in a group of 20 healthy newborn infants with nonhaemolytic jaundice in the first 5 days of life. The evaluation of albumin-bilirubin binding capacity was done by gel filtration technique (Kernlute test, Ameis-Yissum, Jerusalem, Israel) before and after oral administration of a single dose of 15 mg/kg bucolome corresponding to the dosage of 30 mg/kg per day that we used in our previous study. The results of the study are given in the Table. Our experience does not absolutely exclude a reduction of albumin-bilirubin binding capacity caused by bucolome; nevertheless it shows that, if there is such a We welcome the letter of Drs Branski, Hatch, and Lebenthal. In the main they comment on two important issues. We agree, of course, that clinical intolerance to disaccharides may be a primary or secondary phenomenon, and that it can be related to a variety of pathophysiological events. We assumed that this would be evident to readers when categorising our patients. Clinical intolerance to disaccharides is not sylnonymous with the in vitro activity of the substrate-specific enzyme activity assayed in intestinal biopsies obtained from the proximal small gut. Hydrolysis ofingested oligosaccharides is an extremely efficient physiological process, and clinical intolerance of ingested oligosaccharides will only occur when there is extensive reduction in the brush border membrane activity of disaccharidases. In clinical practice the important issue is whether ingested sugars provoke gastrointestinal symptoms, not what the activity of a particular enzyme is in an in vitro laboratory assay system. Our category 2 patients did not clinically respond to elimination of disaccharides from their diets.
This does not necessarily imply that they were not intolerant to disaccharides, but does indicate that other pathophysiological factors were operating in the genesis of the protracted diarrhoea.
We also agree that small intestinal biopsy can be a very useful procedure in the diagnosis and management of protracted diarrhoea in infancy. It should be stressed, however, that a biopsy is not mandatory to the diagnosis and management of very sick infants with protracted diarrhoea, and that an empirical approach based on currently available knowledge is sometimes unavoidable. Theprocedure is not without risk in severely malnourished infants such as tI4ose reported in our publication. Unfortunately a. detailed diagnostic work-up is not always 
